Nutriband Inc (NTRB)
NASDAQ:NTRB
Want to see NTRB full AI Analyst Report?
Top Page
Nutriband
(NASDAQ:NTRB)
Select Model
Select Model
Rating:46Neutral
Price Target:
$6.00
▲(35.75% Upside)
Action:Reiterated
Date:08/20/25
Nutriband's overall stock score of 46 reflects significant challenges tempered by some positive developments. The primary drag is weak financial performance (score: 40, weight: 0.4), driven by severe profitability issues and negative cash flows, despite a stable balance sheet. Technical analysis (score: 45, weight: 0.3) indicates bearish momentum with the stock trading below key moving averages. Valuation concerns (score: 42, weight: 0.2) due to negative earnings further weigh on the score. A positive corporate event (score: 70, weight: 0.1) regarding new preferred stock offers some upside potential but is insufficient to offset broader risks.
Positive Factors
Business Model Strength
Nutriband's focus on transdermal drug delivery systems offers a unique value proposition in healthcare, enhancing patient compliance and therapeutic outcomes.
Negative Factors
Profitability Challenges
Ongoing operational losses and negative cash flows indicate difficulty in achieving profitability, impacting long-term business sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Business Model Strength
Nutriband's focus on transdermal drug delivery systems offers a unique value proposition in healthcare, enhancing patient compliance and therapeutic outcomes.
Read all positive factors
Nutriband (NTRB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$41.57M
Dividend YieldN/A
Average Volume (3M)31.62K
Price to Earnings (P/E)―
Beta (1Y)1.56
Revenue Growth-4.81%
EPS Growth-169.64%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding12,155,983
10 Day Avg. Volume33,995
30 Day Avg. Volume31,617
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)8.35
Price to Sales (P/S)27.38
P/FCF Ratio-10.86
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue18.93
Enterprise Value/Gross Profit68.06
Enterprise Value/Ebitda-4.81
Forecast
1Y Price Target
$15.00Price Target Upside239.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nutriband Business Overview & Revenue Model
Company Description
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release...
How the Company Makes Money
Nutriband generates revenue through the commercialization of its transdermal patch products. The company primarily earns money by selling its patches directly to healthcare providers and distributors, as well as through partnerships with pharmaceu...
Nutriband Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
65
Positive
Cash Flow
25
Negative
| Breakdown | Jan 2026 | Jan 2024 | Jan 2023 | Jan 2022 | Jan 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.04M | 2.14M | 2.09M | 2.08M | 1.42M |
| Gross Profit | 566.31K | 699.30K | 862.11K | 750.41K | 504.31K |
| EBITDA | -8.01M | -10.18M | -5.12M | -4.11M | -5.74M |
| Net Income | -8.23M | -10.48M | -5.49M | -4.81M | -8.42M |
Balance Sheet | |||||
| Total Assets | 7.55M | 7.47M | 7.52M | 9.46M | 12.74M |
| Cash, Cash Equivalents and Short-Term Investments | 4.57M | 4.31M | 492.94K | 1.99M | 4.89M |
| Total Debt | 209.63K | 186.35K | 241.28K | 185.81K | 134.57K |
| Total Liabilities | 868.45K | 1.04M | 1.08M | 883.39K | 880.38K |
| Stockholders Equity | 6.68M | 6.43M | 6.44M | 8.57M | 11.86M |
Cash Flow | |||||
| Free Cash Flow | -5.13M | -4.72M | -3.58M | -3.07M | -2.89M |
| Operating Cash Flow | -5.13M | -4.63M | -3.53M | -2.99M | -2.81M |
| Investing Cash Flow | -5.32K | -92.04K | -51.76K | -79.30K | -81.59K |
| Financing Cash Flow | 5.40M | 8.54M | 2.09M | 160.07K | 7.63M |
Nutriband Technical Analysis
Negative
4.42
Price Trends
3.84
Negative
4.14
Negative
5.22
Negative
Market Momentum
-0.12
Positive
37.31
Neutral
6.56
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTRB, the sentiment is Negative. The current price of 4.42 is above the 20-day moving average (MA) of 3.77, above the 50-day MA of 3.84, and below the 200-day MA of 5.22, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 37.31 is Neutral, neither overbought nor oversold. The STOCH value of 6.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NTRB.
Nutriband Risk Analysis
Nutriband disclosed 36 risk factors in its most recent earnings report. Nutriband reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nutriband Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $269.13M | -1.52 | -124.06% | ― | ― | 39.66% | |
53 Neutral | $180.73M | -2.46 | -91.12% | ― | ― | ― | |
53 Neutral | $160.64M | -4.32 | -48.20% | ― | 7336.90% | 49.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $84.29M | -90.96 | -57.20% | ― | -1.10% | -135.24% | |
46 Neutral | $41.57M | -6.78 | -183.69% | ― | -4.81% | -169.64% | |
44 Neutral | $73.07M | -0.97 | -59.06% | ― | ― | 49.00% |
* Healthcare Sector Average
NTRB
Nutriband
3.45
-1.91
-35.63%
CSBR
Champions Oncology
5.98
0.00
0.00%
IFRX
InflaRx
2.37
0.68
40.24%
PLRX
Pliant Therapeutics
1.15
-0.18
-13.53%
ALXO
ALX Oncology Holdings
1.96
1.55
378.05%
ADAG
Adagene
3.40
1.74
104.82%
Nutriband Corporate Events
Business Operations and StrategyM&A Transactions
Nutriband Divests Pocono Stake to Fund AVERSA Fentanyl
Positive
Dec 30, 2025
On December 29, 2025, Nutriband Inc. announced that it has signed an agreement to sell a 90% stake in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million, with closing expected on December 31, 2025. Following the transaction, Nu...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Nutriband Advances with FDA on Fentanyl Patch
Positive
Oct 28, 2025
Nutriband Inc. announced the successful completion of a meeting with the US FDA regarding its AVERSA™ FENTANYL patch, an abuse-deterrent transdermal system. The meeting, held on September 18, 2025, provided Nutriband with feedback on its Che...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.